Live federal data · NADAC weekly · Part D CY24

Lacosamide Levetiracetam

Lacosamide vs Levetiracetam — $636.5M of combined CY2024 Part D plan spend across 2 molecules. Side-by-side data, every number traced to its CMS or FDA source.

Last updated
NADAC: refreshed weeklyPart D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1
Drug 2
Drug 3 (optional)
Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed
Compare across
11 dimensions
Anticonvulsant
Lacosamide
Brand: MOTPOLY XR
First FDA approval:
Anticonvulsant
Levetiracetam
Brand: Keppra
First FDA approval:
Lowest NADACAcquisition cost floor across all NDCs
$0.084Per unit
$0.030Per unit
Average NADACAcross all dosage forms and strengths
$2.55Up to $21.51
$0.916Up to $19.87
Generic manufacturersActive ANDA holders — FDA Orange Book
2871 total ANDAs filed
52138 total ANDAs filed
Annualized Part D spendCY2024 — CMS Part D Spending Dashboard
$252.2MFull year
$384.3MFull year
Part D claims (CY24)Total fills, all strengths
1.4M243K beneficiaries
7.4M1.6M beneficiaries
Avg cost per claimCalculated: total spend ÷ total claims
$174Per claim, all NDCs
$52Per claim, all NDCs
Part D plans surveyed2026 plan year — CMS Formulary file
329Across CMS plan year
329Across CMS plan year
Prior-authorization frictionPlan-NDC pairs requiring PA
12Minimal friction
102Substantial friction
Step therapy appliedPlan-NDC pairs requiring step therapy
7Limited friction
159Limited friction
FDA shortage statusLive cross-reference vs FDA Drug Shortage Database
NoneClear
NoneClear
Generic availableFDA Orange Book
Yes28 manufacturers
Yes52 manufacturers